Study S002784

Investigating the Effect of Post-dose Meal Timings and Water Volume at Dosing on the Pharmacokinetic Properties of Oral Zenagamtide in Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07815067
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 320
Start: 2026-09-07
Primary completion: 2028-06-12
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Zenagamtide injection; DRUG:Zenagamtide tablet
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1316-5947; OTHER:2025-521383-35; NIH:2025

Registered primary outcomes

AUC, zenagamtide, steady state (ss): area under the zenagamtide plasma concentration-time curve during a dosing interval at steady state [From 0 (pre-dose) up to Day 196 and Day 224]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.